Global Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Data 2025, Forecast To 2034
26 Mar, 2025
What are the Historical Developments and Current Growth Metrics of the Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
The transthyretin amyloid cardiomyopathy attrcm treatment market has seen considerable growth due to a variety of factors.
• The market size for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) has experienced a dramatic expansion in the recent past. It is expected to escalate from $10.36 billion in 2024 to $13.32 billion in 2025, manifesting a compound annual growth rate (CAGR) of 28.5%.
The significant growth in the historic timeline is associated with the increased occurrence of transthyretin amyloid cardiomyopathy, a rise in the incidence of transthyretin amyloidosis among the elderly, elevated awareness among healthcare providers and patients, alongside enhancing and amplifying healthcare services.
What is the Forecasted Market Size and CAGR for the Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
The transthyretin amyloid cardiomyopathy attrcm treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is projected to experience remarkable growth in the coming years. The expected growth will elevate the market size to $35.93 billion in 2029, with a compound annual growth rate (CAGR) of 28.2%.
Factors contributing to this growth in the forecast period include a rising incidence of transthyretin amyloidosis, an increase in the diagnosis of neuropathic conditions, an expanding aging demographic, higher demand for designated drugs to manage rare disorder symptoms, and growing healthcare needs. Key trends to watch in the forecast period are emerging diagnostic technologies, the introduction of novel therapeutic management techniques, innovative targeted treatments for transthyretin amyloidosis, and advancements in diagnostic methods like cardiac MRI techniques.
What Key Factors and Trends Are Driving The Growth Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
The increasing incidence of long-term diseases is anticipated to stimulate expansion in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Long-term conditions are characterized by a slow pace of progression, lasting more than a year and often require consistent medical attention. Factors contributing to the increase in chronic ailments include aging populations, inactive lifestyles, poor dietary habits, increasing rates of obesity, and exposure to environmental pollutants. ATTR-CM treatment aids by stabilizing transthyretin, reducing amyloid accumulation, enhancing heart functionality, and easing symptoms to improve management of associated chronic conditions. For example, in September 2023, data from the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported 41 million deaths, 74% of which were due to non-communicable diseases (NCDs) or chronic ailments. Worldwide, cardiovascular diseases resulted in 17.9 million deaths, cancer caused 9.3 million deaths, chronic respiratory diseases led to 4.1 million deaths, and diabetes claimed 2.0 million lives. Hence, the escalating incidence of chronic diseases is steering growth in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
What Are The Market Segments In The Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
What New Trends Are Influencing The Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
Leading firms in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry are directing their efforts towards developing groundbreaking solutions for ATTR-CM, such as orally taken prescribed drugs that specifically target and stabilize the transthyretin (TTR) proteins or diminish the accumulation of amyloid fibril in the heart. These medications are prescribed by healthcare professionals and are usually consumed in the forms of tablets, liquid solutions, or capsules. For instance, in November 2024, the U.S. Food and Drug Administration sanctioned Attruby (acoramidis), a drug produced by BridgeBio Pharma Inc., a biotechnology firm based in the U.S., for the treatment of ATTR-CM in adult patients. This drug stabilizes the TTR protein and consequently reduces the rates of heart-related fatalities and hospital admissions. It was found to be easily tolerated in clinical trials and provides quick relief by addressing the fundamental cause of the disease.
Who Are the Key Players In The Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are:
• Pfizer Inc.
• Bayer AG.
• AstraZeneca Plc
• GlaxoSmithKline Plc.
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Regeneron Pharmaceuticals Inc.
• MedStar Health Inc
• Alnylam Pharmaceuticals Inc
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc
• BridgeBio Pharma Inc.
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• Alexion Pharmaceuticals Inc.
• Neurimmune Holding AG
• SOM Biotech S.L
• Corino Therapeutics Inc
• Eidos Therapeutics Inc
• CRISPR Therapeutics AG
What Are The Regional Insights Into The Transthyretin Amyloid Cardiomyopathy ATTRCM Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.